(Q36301502)

English

The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore (English)

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

0 references

chronic hepatitis B

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

author name string

L F Lacey

1

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

E Gane

2

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

publication date

1 November 2007

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

14

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

11

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

751-766

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2156151

30 September 2017

Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2156151

30 September 2017

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2156151

30 September 2017

Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2156151

30 September 2017

Management of antiviral resistance in patients with chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2156151

30 September 2017

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2156151

30 September 2017

EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2156151

30 September 2017

Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2156151

30 September 2017

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2156151

29 June 2018

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2156151

29 June 2018

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00865.X

21 January 2018

A cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00865.X

21 January 2018

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00865.X

21 January 2018

Cost-effectiveness in hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00865.X

21 January 2018

Durability of serologic response after lamivudine treatment of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00865.X

21 January 2018

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00865.X

21 January 2018

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00865.X

21 January 2018

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00865.X

21 January 2018

Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2156151

22 September 2018

The natural history of chronic hepatitis B virus infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/17927611

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of chronic hepatitis B

1 reference

https://pubmed.ncbi.nlm.nih.gov/17927611

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B

1 reference

https://pubmed.ncbi.nlm.nih.gov/17927611

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2893.2007.00865.X

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36301502&oldid=1694497769"